Physician

Adetokunbo Adenike Odunaiya, MD

According to 2025 Medicare claims, Adetokunbo Odunaiya, MD (NPI: 1821302571) practices nephrology in the San Jose-Sunnyvale-Santa Clara, CA market, with the plurality of this provider's patient population coming from Santa Clara, CA. This provider's primary affiliated billing organization is STANFORD HEALTH CARE (NPI: 1437292927; TIN: 770465765) and primary practice location at 94305-2200.

Odunaiya's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 242 traditional Medicare patients, billed 676 HCPCS/CPT codes, and received $57,820 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 974 prescription claims across 97 beneficiaries totaling $116,499 in drug costs, led by Farxiga (Dapagliflozin Propanediol). DME data shows 3,785 claims. Open Payments data shows 2 records totaling $252. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $15,988 and ending at $57,820. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $12,421 and ending at $116,499. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	60	214	$15,988
2018	188	794	$66,149
2019	225	732	$59,780
2020	214	767	$65,711
2021	232	773	$66,675
2022	208	557	$41,623
2023	240	798	$62,205
2024	242	676	$57,820

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	38	$12,421
2018	53	544	$145,019
2019	76	849	$185,412
2020	87	976	$143,602
2021	104	1,154	$99,466
2022	99	1,124	$127,650
2023	92	1,014	$109,483
2024	97	974	$116,499

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	128	546	$26,373
2019	244	1,472	$95,478
2020	264	2,495	$215,700
2021	339	2,996	$247,004
2022	369	3,221	$190,003
2023	376	4,002	$204,149
2024	399	3,785	$183,698

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	23	25	$153
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	44	46	$116
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	133	239	$94
99221	Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes	12	12	$73
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	84	303	$71

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Farxiga	Dapagliflozin Propanediol	38	1,197	$20,272
Lokelma	Sodium Zirconium Cyclosilicate	21	630	$14,982
Ozempic	Semaglutide	12	350	$10,601
Tacrolimus	Tacrolimus	71	3,810	$10,040
Retacrit	Epoetin Alfa-Epbx	11	322	$8,101

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7503	Tacrolimus, extended release, (envarsus xr), oral, 0.25 mg	N	20	247	$128,983
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	96	1,239	$16,039
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	89	690	$12,091
J7507	Tacrolimus, immediate release, oral, 1 mg	N	75	601	$11,199
J7517	Mycophenolate mofetil, oral, 250 mg	N	69	566	$9,068

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	2	$252	Mallinckrodt Hospital Products Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Adetokunbo Adenike Odunaiya, MD?

Tedicare shows public-source Medicare data for Adetokunbo Adenike Odunaiya, MD (NPI 1821302571), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Adetokunbo Adenike Odunaiya, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Adetokunbo Adenike Odunaiya, MD?

Adetokunbo Adenike Odunaiya, MD is linked to STANFORD HEALTH CARE (billing NPI 1437292927) in the available physician profile data.

Does Adetokunbo Adenike Odunaiya, MD have Open Payments data?

Adetokunbo Adenike Odunaiya, MD has 2 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.